戻る
TG Therapeutics Inc (TGTX)価格
TGTX 株価推移チャート
TGTX 収入
TG Therapeutics Inc
$30.57
-0.45%
$-0.14
終値： Jan 16, 16:00:00 GMT-5
$30.57
0%
$0
アフターマーケット：Jan 16, 20:00:00 GMT-5
主要データ
前終値
$30.71
始値
$30.99
当日レンジ
$30.3 - $31.25
52週レンジ
$25.28 - $46.48
取引高
2.4M
平均取引高
2.0M
1株当たり利益(TTM)
2.78
配当利回り
--
時価総額
$4.8B
TGTXとは何ですか？
TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in Morrisville, North Carolina and currently employs 374 full-time employees. The firm is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. The company also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition, and/or investment opportunities.